Article: Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options

Article - Media

Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrated 100% inhibition of SARS-CoV-2 virus infection.

The Sorrento Analyst

H.C. Wainwright analyst Raghuram Selvaraju has a Buy rating on Sorrento with a $24 price target.

Comment: Every placement  these guys do seems to sour.  Time for an investigation?

Competing Comment: Every placement is subject to naked short selling pressure, without an investigation you cannot know for sure.  Some companies do have histories. HCWainwreight appears to be one of them.

THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?